Skip to main content
SpringerLink
Log in

Surgical Consideration in Renal Tumors

  • Chapter
  • First Online:
Book cover Kidney Cancer

  • 1003 Accesses

Abstract

This chapter addresses the surgical management of localized, locally advanced, and metastatic renal cell carcinoma. Multiple management options are available for clinical T1 renal mass. Partial nephrectomy is the treatment of choice for the management of clinical T1 renal cell carcinoma. Alternative nephron-sparing procedures for patients with clinical T1 renal cell carcinoma include thermal ablative therapies, such as radiofrequency ablation and renal cryosurgery. Active surveillance is an acceptable management option for small renal masses <4 cm in unfit patients or those with limited life expectancy. Radical nephrectomy is still the first choice for patients with localized renal cell carcinoma with large size or unsuitable location for nephron-sparing surgery. Radical nephrectomy and inferior vena cava thrombectomy are possible solutions for renal cell carcinoma and inferior vena cava thrombus.

Complete en bloc resection may be the surgical goal of treatment for locally invasive renal cell carcinoma. Even though the role of cytoreductive nephrectomy and metastasectomy still remains controversial, surgical resection of the primary tumor and metastases is considered important for cure or long-term survival.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373(9669):1119–32. https://doi.org/10.1016/S0140-6736(09)60229-4.

    Article  CAS  PubMed  Google Scholar 

  2. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105. https://doi.org/10.1016/j.eururo.2016.02.029.

    Article  PubMed  Google Scholar 

  3. International Agency for Research on Cancer (IARC). GLOBOCAN database 2012. http://globocan.iarc.fr. Accessed Nov 2017.

  4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. https://doi.org/10.3322/caac.21387.

    Article  PubMed  Google Scholar 

  5. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer. 2008;113(1):78–83. https://doi.org/10.1002/cncr.23518.

    Article  PubMed  Google Scholar 

  6. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 1999;17(8):2530–40. https://doi.org/10.1200/JCO.1999.17.8.2530.

    Article  CAS  Google Scholar 

  7. Marchioni M, Bandini M, Pompe RS, Tian Z, Martel T, Kapoor A, et al. Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. Int Urol Nephrol. 2017;49(12):2143–9. https://doi.org/10.1007/s11255-017-1703-y.

    Article  PubMed  Google Scholar 

  8. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24. https://doi.org/10.1056/NEJMoa065044.

    Article  CAS  PubMed  Google Scholar 

  9. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34. https://doi.org/10.1056/NEJMoa060655.

    Article  CAS  PubMed  Google Scholar 

  10. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(6):1061–8. https://doi.org/10.1200/JCO.2009.23.9764.

    Article  CAS  Google Scholar 

  11. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol. 2006;176(6 Pt 1):2353–8. https://doi.org/10.1016/j.juro.2006.07.130.

    Article  PubMed  Google Scholar 

  12. Russo P, Jang TL, Pettus JA, Huang WC, Eggener SE, O’Brien MF, et al. Survival rates after resection for localized kidney cancer: 1989 to 2004. Cancer. 2008;113(1):84–96. https://doi.org/10.1002/cncr.23520.

    Article  PubMed  Google Scholar 

  13. Kunkle DA, Uzzo RG. Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. Cancer. 2008;113(10):2671–80. https://doi.org/10.1002/cncr.23896.

    Article  PubMed  Google Scholar 

  14. Renal mass and localized renal cancer: American Urological Association Guideline. http://www.auanet.org/guidelines/renal-mass-and-localized-renal-cancer-new-(2017). Accessed Nov 2017.

  15. Gill IS, Aron M, Gervais DA, Jewett MA. Clinical practice. Small renal mass. N Engl J Med. 2010;362(7):624–34. https://doi.org/10.1056/NEJMcp0910041.

    Article  CAS  PubMed  Google Scholar 

  16. Lane BR, Samplaski MK, Herts BR, Zhou M, Novick AC, Campbell SC. Renal mass biopsy--a renaissance? J Urol. 2008;179(1):20–7. https://doi.org/10.1016/j.juro.2007.08.124.

    Article  PubMed  Google Scholar 

  17. Schmidbauer J, Remzi M, Memarsadeghi M, Haitel A, Klingler HC, Katzenbeisser D, et al. Diagnostic accuracy of computed tomography-guided percutaneous biopsy of renal masses. Eur Urol. 2008;53(5):1003–11. https://doi.org/10.1016/j.eururo.2007.11.041.

    Article  PubMed  Google Scholar 

  18. Uzzo RG, Novick AC. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol. 2001;166(1):6–18.

    Article  CAS  PubMed  Google Scholar 

  19. Hafez KS, Krishnamurthi V, Campbell SC, Novick AC. Contemporary management of renal cell carcinoma with coexistent renal artery disease: update of the Cleveland Clinic experience. Urology. 2000;56(3):382–6.

    Article  CAS  PubMed  Google Scholar 

  20. Fergany A. Current status and advances in nephron-sparing surgery. Clin Genitourin Cancer. 2006;5(1):26–33. https://doi.org/10.3816/CGC.2006.n.014.

    Article  PubMed  Google Scholar 

  21. Huang Y, Murakami T, Sano F, Kondo K, Nakaigawa N, Kishida T, et al. Expression of aquaporin 1 in primary renal tumors: a prognostic indicator for clear-cell renal cell carcinoma. Eur Urol. 2009;56(4):690–8. https://doi.org/10.1016/j.eururo.2008.10.014.

    Article  CAS  PubMed  Google Scholar 

  22. Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc. 2000;75(12):1236–42.

    Article  CAS  PubMed  Google Scholar 

  23. Lee SH, Son HS, Cho S, Kim SJ, Yoo DS, Kang SH, et al. Which patients should we follow up beyond 5 years after definitive therapy for localized renal cell carcinoma? Cancer Res Treat. 2015;47(3):489–94. https://doi.org/10.4143/crt.2014.013.

    Article  CAS  PubMed  Google Scholar 

  24. Mitchell RE, Gilbert SM, Murphy AM, Olsson CA, Benson MC, McKiernan JM. Partial nephrectomy and radical nephrectomy offer similar cancer outcomes in renal cortical tumors 4 cm or larger. Urology. 2006;67(2):260–4. https://doi.org/10.1016/j.urology.2005.08.057.

    Article  PubMed  Google Scholar 

  25. Van Poppel H, Joniau S. Is surveillance an option for the treatment of small renal masses? Eur Urol. 2007;52(5):1323–30. https://doi.org/10.1016/j.eururo.2007.07.025.

    Article  PubMed  Google Scholar 

  26. Pahernik S, Roos F, Rohrig B, Wiesner C, Thuroff JW. Elective nephron sparing surgery for renal cell carcinoma larger than 4 cm. J Urol. 2008;179(1):71–4; discussion 4. https://doi.org/10.1016/j.juro.2007.08.165.

    Article  PubMed  Google Scholar 

  27. Peycelon M, Hupertan V, Comperat E, Renard-Penna R, Vaessen C, Conort P, et al. Long-term outcomes after nephron sparing surgery for renal cell carcinoma larger than 4 cm. J Urol. 2009;181(1):35–41. https://doi.org/10.1016/j.juro.2008.09.025.

    Article  PubMed  Google Scholar 

  28. Crispen PL, Wong YN, Greenberg RE, Chen DY, Uzzo RG. Predicting growth of solid renal masses under active surveillance. Urol Oncol. 2008;26(5):555–9. https://doi.org/10.1016/j.urolonc.2008.03.010.

    Article  PubMed  PubMed Central  Google Scholar 

  29. VanderBrink BA, Munver R, Tash JA, Sosa RE. Renal angiomyolipoma with contrast-enhancing elements mimicking renal malignancy: radiographic and pathologic evaluation. Urology. 2004;63(3):584–6. https://doi.org/10.1016/j.urology.2003.10.051.

    Article  PubMed  Google Scholar 

  30. Desai MM, Gill IS, Ramani AP, Matin SF, Kaouk JH, Campero JM. Laparoscopic radical nephrectomy for cancer with level I renal vein involvement. J Urol. 2003;169(2):487–91. https://doi.org/10.1097/01.ju.0000041955.93458.f5.

    Article  PubMed  Google Scholar 

  31. Gill IS, Aron M. Against the motion: open partial nephrectomy is the standard of care for small resectable solid renal masses. Eur Urol. 2007;51(2):562–4; discussion 4

    PubMed  Google Scholar 

  32. Lane BR, Campbell SC, Gill IS. 10-year oncologic outcomes after laparoscopic and open partial nephrectomy. J Urol. 2013;190(1):44–9. https://doi.org/10.1016/j.juro.2012.12.102.

    Article  PubMed  Google Scholar 

  33. Bollens R, Rosenblatt A, Espinoza BP, De Groote A, Quackels T, Roumeguere T, et al. Laparoscopic partial nephrectomy with “on-demand” clamping reduces warm ischemia time. Eur Urol. 2007;52(3):804–9. https://doi.org/10.1016/j.eururo.2007.04.011.

    Article  PubMed  Google Scholar 

  34. Breda A, Stepanian SV, Lam JS, Liao JC, Gill IS, Colombo JR, et al. Use of haemostatic agents and glues during laparoscopic partial nephrectomy: a multi-institutional survey from the United States and Europe of 1347 cases. Eur Urol. 2007;52(3):798–803. https://doi.org/10.1016/j.eururo.2007.02.035.

    Article  PubMed  Google Scholar 

  35. Abdi R, Dong VM, Rubel JR, Kittur D, Marshall F, Racusen LC. Correlation between glomerular size and long-term renal function in patients with substantial loss of renal mass. J Urol. 2003;170(1):42–4. https://doi.org/10.1097/01.ju.0000069821.97385.6b.

    Article  PubMed  Google Scholar 

  36. Goldfarb DA. Preservation of renal function and the risk of hyperfiltration nephropathy. Semin Urol Oncol. 1995;13(4):292–5.

    CAS  PubMed  Google Scholar 

  37. Thompson RH, Blute ML. At what point does warm ischemia cause permanent renal damage during partial nephrectomy? Eur Urol. 2007;52(4):961–3. https://doi.org/10.1016/j.eururo.2007.04.051.

    Article  PubMed  Google Scholar 

  38. Lane BR, Babineau DC, Poggio ED, Weight CJ, Larson BT, Gill IS, et al. Factors predicting renal functional outcome after partial nephrectomy. J Urol. 2008;180(6):2363–8; discussion 8-9. https://doi.org/10.1016/j.juro.2008.08.036.

    Article  PubMed  Google Scholar 

  39. Lane BR, Novick AC. Nephron-sparing surgery. BJU Int. 2007;99(5 Pt B):1245–50. https://doi.org/10.1111/j.1464-410X.2007.06831.x.

    Article  PubMed  Google Scholar 

  40. Thompson RH, Frank I, Lohse CM, Saad IR, Fergany A, Zincke H, et al. The impact of ischemia time during open nephron sparing surgery on solitary kidneys: a multi-institutional study. J Urol. 2007;177(2):471–6. https://doi.org/10.1016/j.juro.2006.09.036.

    Article  PubMed  Google Scholar 

  41. Funahashi Y, Yoshino Y, Sassa N, Matsukawa Y, Takai S, Gotoh M. Comparison of warm and cold ischemia on renal function after partial nephrectomy. Urology. 2014;84(6):1408–12. https://doi.org/10.1016/j.urology.2014.08.040.

    Article  PubMed  Google Scholar 

  42. Castilla EA, Liou LS, Abrahams NA, Fergany A, Rybicki LA, Myles J, et al. Prognostic importance of resection margin width after nephron-sparing surgery for renal cell carcinoma. Urology. 2002;60(6):993–7.

    Article  PubMed  Google Scholar 

  43. Hinshaw JL, Lee FT Jr. Image-guided ablation of renal cell carcinoma. Magn Reson Imaging Clin N Am. 2004;12(3):429–47, vi. https://doi.org/10.1016/j.mric.2004.03.003.

    Article  PubMed  Google Scholar 

  44. Lowry PS, Nakada SY. Renal cryotherapy: 2003 clinical status. Curr Opin Urol. 2003;13(3):193–7. https://doi.org/10.1097/01.mou.0000068745.22370.75.

    Article  PubMed  Google Scholar 

  45. Raman JD, Raj GV, Lucas SM, Williams SK, Lauer EM, Ahrar K, et al. Renal functional outcomes for tumours in a solitary kidney managed by ablative or extirpative techniques. BJU Int. 2010;105(4):496–500. https://doi.org/10.1111/j.1464-410X.2009.08776.x.

    Article  PubMed  Google Scholar 

  46. Sterrett SP, Nakada SY, Wingo MS, Williams SK, Leveillee RJ. Renal thermal ablative therapy. Urol Clin North Am. 2008;35(3):397–414, viii. https://doi.org/10.1016/j.ucl.2008.05.005.

    Article  PubMed  Google Scholar 

  47. Johnson DB, Solomon SB, Su LM, Matsumoto ED, Kavoussi LR, Nakada SY, et al. Defining the complications of cryoablation and radio frequency ablation of small renal tumors: a multi-institutional review. J Urol. 2004;172(3):874–7. https://doi.org/10.1097/01.ju.0000135833.67906.ec.

    Article  PubMed  Google Scholar 

  48. Beisland C, Hjelle KM, Reisaeter LA, Bostad L. Observation should be considered as an alternative in management of renal masses in older and comorbid patients. Eur Urol. 2009;55(6):1419–27. https://doi.org/10.1016/j.eururo.2008.12.031.

    Article  PubMed  Google Scholar 

  49. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol. 1969;101(3):297–301.

    Article  CAS  PubMed  Google Scholar 

  50. Choi SY, Yoo S, You D, Jeong IG, Song C, Hong B, et al. Adaptive functional change of the contralateral kidney after partial nephrectomy. Am J Physiol Renal Physiol. 2017;313(2):F192–F8. https://doi.org/10.1152/ajprenal.00058.2017.

    Article  CAS  PubMed  Google Scholar 

  51. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305. https://doi.org/10.1056/NEJMoa041031.

    Article  CAS  PubMed  Google Scholar 

  52. O’Malley RL, Godoy G, Kanofsky JA, Taneja SS. The necessity of adrenalectomy at the time of radical nephrectomy: a systematic review. J Urol. 2009;181(5):2009–17. https://doi.org/10.1016/j.juro.2009.01.018.

    Article  PubMed  Google Scholar 

  53. Lam JS, Klatte T, Patard JJ, Goel RH, Guille F, Lobel B, et al. Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur Urol. 2007;52(1):155–62. https://doi.org/10.1016/j.eururo.2007.01.106.

    Article  PubMed  Google Scholar 

  54. Lane BR, Tiong HY, Campbell SC, Fergany AF, Weight CJ, Larson BT, et al. Management of the adrenal gland during partial nephrectomy. J Urol. 2009;181(6):2430–6; discussion 6-7. https://doi.org/10.1016/j.juro.2009.02.027.

    Article  PubMed  Google Scholar 

  55. Leibovich BC, Blute ML. Lymph node dissection in the management of renal cell carcinoma. Urol Clin North Am. 2008;35(4):673–8; viii. https://doi.org/10.1016/j.ucl.2008.07.011.

    Article  PubMed  Google Scholar 

  56. Blom JH, van Poppel H, Marechal JM, Jacqmin D, Schroder FH, de Prijck L, et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol. 2009;55(1):28–34. https://doi.org/10.1016/j.eururo.2008.09.052.

    Article  PubMed  Google Scholar 

  57. Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H. A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. J Urol. 2004;172(2):465–9. https://doi.org/10.1097/01.ju.0000129815.91927.85.

    Article  PubMed  Google Scholar 

  58. Hemal AK, Kumar A, Kumar R, Wadhwa P, Seth A, Gupta NP. Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison. J Urol. 2007;177(3):862–6. https://doi.org/10.1016/j.juro.2006.10.053.

    Article  CAS  PubMed  Google Scholar 

  59. Hemal AK, Kumar A, Gupta NP, Kumar R. Oncologic outcome of 132 cases of laparoscopic radical nephrectomy with intact specimen removal for T1-2N0M0 renal cell carcinoma. World J Urol. 2007;25(6):619–26. https://doi.org/10.1007/s00345-007-0210-7.

    Article  PubMed  Google Scholar 

  60. Fugita OE, Chan DY, Roberts WW, Kavoussi LR, Jarrett TW. Laparoscopic radical nephrectomy in obese patients: outcomes and technical considerations. Urology. 2004;63(2):247–52; discussion 52. https://doi.org/10.1016/j.urology.2003.09.077.

    Article  PubMed  Google Scholar 

  61. Gabr AH, Elsayed ER, Gdor Y, Roberts WW, Wolf JS Jr. Obesity and morbid obesity are associated with a greater conversion rate to open surgery for standard but not hand assisted laparoscopic radical nephrectomy. J Urol. 2008;180(6):2357–62; discussion 62. https://doi.org/10.1016/j.juro.2008.08.077.

    Article  PubMed  Google Scholar 

  62. Porter MP, Lin DW. Trends in renal cancer surgery and patient provider characteristics associated with partial nephrectomy in the United States. Urol Oncol. 2007;25(4):298–302. https://doi.org/10.1016/j.urolonc.2006.07.016.

    Article  PubMed  Google Scholar 

  63. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol. 1998;159(4):1163–7.

    Article  CAS  PubMed  Google Scholar 

  64. Stephenson AJ, Chetner MP, Rourke K, Gleave ME, Signaevsky M, Palmer B, et al. Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol. 2004;172(1):58–62. https://doi.org/10.1097/01.ju.0000132126.85812.7d.

    Article  PubMed  Google Scholar 

  65. Zini L, Destrieux-Garnier L, Leroy X, Villers A, Haulon S, Lemaitre L, et al. Renal vein ostium wall invasion of renal cell carcinoma with an inferior vena cava tumor thrombus: prediction by renal and vena caval vein diameters and prognostic significance. J Urol. 2008;179(2):450–4; discussion 4. https://doi.org/10.1016/j.juro.2007.09.042.

    Article  PubMed  Google Scholar 

  66. Wein AJ, Kavoussi LR, Partin AW, Peters CA. Campbell-Walsh urology. Philadelphia, PA : Elsevier; Vol. 4. 2016.

    Google Scholar 

  67. Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol. 2005;174(5):1759–63; discussion 63. https://doi.org/10.1097/01.ju.0000177487.64651.3a.

    Article  PubMed  Google Scholar 

  68. Kim HL, Zisman A, Han KR, Figlin RA, Belldegrun AS. Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol. 2004;171(2 Pt 1):588–91. https://doi.org/10.1097/01.ju.0000104672.37029.4b.

    Article  PubMed  Google Scholar 

  69. Blute ML, Leibovich BC, Lohse CM, Cheville JC, Zincke H. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int. 2004;94(1):33–41. https://doi.org/10.1111/j.1464-410X.2004.04897.x.

    Article  PubMed  Google Scholar 

  70. Terakawa T, Miyake H, Takenaka A, Hara I, Fujisawa M. Clinical outcome of surgical management for patients with renal cell carcinoma involving the inferior vena cava. Int J Urol. 2007;14(9):781–4. https://doi.org/10.1111/j.1442-2042.2007.01749.x.

    Article  PubMed  Google Scholar 

  71. Granberg CF, Boorjian SA, Schaff HV, Orszulak TA, Leibovich BC, Lohse CM, et al. Surgical management, complications, and outcome of radical nephrectomy with inferior vena cava tumor thrombectomy facilitated by vascular bypass. Urology. 2008;72(1):148–52. https://doi.org/10.1016/j.urology.2008.01.006.

    Article  PubMed  Google Scholar 

  72. Oto A, Herts BR, Remer EM, Novick AC. Inferior vena cava tumor thrombus in renal cell carcinoma: staging by MR imaging and impact on surgical treatment. AJR Am J Roentgenol. 1998;171(6):1619–24. https://doi.org/10.2214/ajr.171.6.9843299.

    Article  CAS  PubMed  Google Scholar 

  73. Tsili AC, Argyropoulou MI. Advances of multidetector computed tomography in the characterization and staging of renal cell carcinoma. World J Radiol. 2015;7(6):110–27. https://doi.org/10.4329/wjr.v7.i6.110.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Wotkowicz C, Wszolek MF, Libertino JA. Resection of renal tumors invading the vena cava. Urol Clin North Am. 2008;35(4):657–71. ; viii. https://doi.org/10.1016/j.ucl.2008.07.013.

    Article  PubMed  Google Scholar 

  75. Subramanian VS, Stephenson AJ, Goldfarb DA, Fergany AF, Novick AC, Krishnamurthi V. Utility of preoperative renal artery embolization for management of renal tumors with inferior vena caval thrombi. Urology. 2009;74(1):154–9. https://doi.org/10.1016/j.urology.2008.12.084.

    Article  PubMed  Google Scholar 

  76. Gettman MT, Boelter CW, Cheville JC, Zincke H, Bryant SC, Blute ML. Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension. J Urol. 2003;169(4):1282–6. https://doi.org/10.1097/01.ju.0000049093.03392.cc.

    Article  PubMed  Google Scholar 

  77. Slaton JW, Balbay MD, Levy DA, Pisters LL, Nesbitt JC, Swanson DA, et al. Nephrectomy and vena caval thrombectomy in patients with metastatic renal cell carcinoma. Urology. 1997;50(5):673–7.

    Article  CAS  PubMed  Google Scholar 

  78. Margulis V, Sanchez-Ortiz RF, Tamboli P, Cohen DD, Swanson DA, Wood CG. Renal cell carcinoma clinically involving adjacent organs: experience with aggressive surgical management. Cancer. 2007;109(10):2025–30. https://doi.org/10.1002/cncr.22629.

    Article  PubMed  Google Scholar 

  79. May M, Brookman-Amissah S, Pflanz S, Roigas J, Hoschke B, Kendel F. Pre-operative renal arterial embolisation does not provide survival benefit in patients with radical nephrectomy for renal cell carcinoma. Br J Radiol. 2009;82(981):724–31. https://doi.org/10.1259/bjr/17514226.

    Article  CAS  PubMed  Google Scholar 

  80. Dekernion JB, Ramming KP, Smith RB. The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol. 1978;120(2):148–52.

    Article  CAS  PubMed  Google Scholar 

  81. Karellas ME, Jang TL, Kagiwada MA, Kinnaman MD, Jarnagin WR, Russo P. Advanced-stage renal cell carcinoma treated by radical nephrectomy and adjacent organ or structure resection. BJU Int. 2009;103(2):160–4. https://doi.org/10.1111/j.1464-410X.2008.08025.x.

    Article  PubMed  Google Scholar 

  82. Cox CE, Lacy SS, Montgomery WG, Boyce WH. Renal adenocarcinoma: 28-year review, with emphasis on rationale and feasibility of preoperative radiotherapy. J Urol. 1970;104(1):53–61.

    Article  CAS  PubMed  Google Scholar 

  83. van der Werf-Messing B. Proceedings: carcinoma of the kidney. Cancer. 1973;32(5):1056–61.

    Article  PubMed  Google Scholar 

  84. Kao GD, Malkowicz SB, Whittington R, D’Amico AV, Wein AJ. Locally advanced renal cell carcinoma: low complication rate and efficacy of postnephrectomy radiation therapy planned with CT. Radiology. 1994;193(3):725–30. https://doi.org/10.1148/radiology.193.3.7972814.

    Article  CAS  PubMed  Google Scholar 

  85. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, European Organisation for R, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–70.

    Article  CAS  PubMed  Google Scholar 

  86. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–9. https://doi.org/10.1056/NEJMoa003013.

    Article  CAS  PubMed  Google Scholar 

  87. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171(3):1071–6. https://doi.org/10.1097/01.ju.0000110610.61545.ae.

    Article  PubMed  Google Scholar 

  88. Zini L, Capitanio U, Perrotte P, Jeldres C, Shariat SF, Arjane P, et al. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology. 2009;73(2):342–6. https://doi.org/10.1016/j.urology.2008.09.022.

    Article  PubMed  Google Scholar 

  89. Trinh QD, Bianchi M, Hansen J, Tian Z, Abdollah F, Shariat SF, et al. In-hospital mortality and failure to rescue after cytoreductive nephrectomy. Eur Urol. 2013;63(6):1107–14. https://doi.org/10.1016/j.eururo.2012.08.069.

    Article  PubMed  Google Scholar 

  90. Immediate surgery or surgery after sunitinib malate in treating patients with metastatic kidney cancer (SURTIME). Available at http://clinicaltrials.gov/ct2/show/NCT01099423. Accessed Nov 2017.

  91. Clinical trial to assess the importance of nephrectomy (CARMENA). Available at http://clinicaltrials.gov/ct2/show/NCT00930033. Accessed Nov 2017.

  92. Stewart GD, Aitchison M, Bex A, Larkin J, Lawless C, Mejean A, et al. Cytoreductive nephrectomy in the tyrosine kinase inhibitor era: a question that may never be answered. Eur Urol. 2017;71(6):845–7. https://doi.org/10.1016/j.eururo.2016.10.029.

    Article  PubMed  Google Scholar 

  93. Mejean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379(5):417–27. https://doi.org/10.1056/NEJMoa1803675.

    Article  CAS  PubMed  Google Scholar 

  94. You D, Jeong IG, Ahn JH, Lee DH, Lee JL, Hong JH, et al. The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. J Urol. 2011;185(1):54–9. https://doi.org/10.1016/j.juro.2010.09.018.

    Article  PubMed  Google Scholar 

  95. Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011;185(1):60–6. https://doi.org/10.1016/j.juro.2010.09.012.

    Article  PubMed  Google Scholar 

  96. You D, Jeong IG, Song C, Lee JL, Hong B, Hong JH, et al. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era. Jpn J Clin Oncol. 2015;45(1):96–102. https://doi.org/10.1093/jjco/hyu171.

    Article  PubMed  Google Scholar 

  97. Walther MM, Patel B, Choyke PL, Lubensky IA, Vocke CD, Harris C, et al. Hypercalcemia in patients with metastatic renal cell carcinoma: effect of nephrectomy and metabolic evaluation. J Urol. 1997;158(3 Pt 1):733–9.

    CAS  PubMed  Google Scholar 

  98. Barney JD, Churchill BM. Adenocarcinoma of the kidney with metastasis to the lung. J Urol. 1939;42:269–76.

    Article  Google Scholar 

  99. Kim DY, Karam JA, Wood CG. Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. World J Urol. 2014;32(3):631–42. https://doi.org/10.1007/s00345-014-1293-6.

    Article  PubMed  Google Scholar 

  100. Daliani DD, Tannir NM, Papandreou CN, Wang X, Swisher S, Wood CG, et al. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int. 2009;104(4):456–60. https://doi.org/10.1111/j.1464-410X.2009.08490.x.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011;117(13):2873–82. https://doi.org/10.1002/cncr.25836.

    Article  PubMed  Google Scholar 

  102. Dabestani S, Marconi L, Hofmann F, Stewart F, Lam TB, Canfield SE, et al. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol. 2014;15(12):e549–61. https://doi.org/10.1016/S1470-2045(14)70235-9.

    Article  PubMed  Google Scholar 

  103. Yu X, Wang B, Li X, Lin G, Zhang C, Yang Y, et al. The significance of metastasectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy. Biomed Res Int. 2015;2015:176373. https://doi.org/10.1155/2015/176373.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. You D, Lee C, Jeong IG, Song C, Lee JL, Hong B, et al. Impact of metastasectomy on prognosis in patients treated with targeted therapy for metastatic renal cell carcinoma. J Cancer Res Clin Oncol. 2016;142(11):2331–8. https://doi.org/10.1007/s00432-016-2217-1.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

    Dalsan You, Se Young Choi, Jeman Ryu & Choung-Soo Kim

  2. Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, South Korea

    Se Young Choi

Authors
  1. Dalsan You
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Se Young Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeman Ryu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Choung-Soo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Choung-Soo Kim .

Editor information

Editors and Affiliations

  1. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Medical College of Cornell University, Houston, TX, USA

    Mukul K. Divatia

  2. Gulhane Military Medical Academy, School of Medicine, Department of Pathology, Ankara, Turkey

    Ayhan Ozcan

  3. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Charles C. Guo

  4. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Medical College of Cornell University, Houston, TX, USA

    Jae Y. Ro

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

You, D., Choi, S.Y., Ryu, J., Kim, CS. (2020). Surgical Consideration in Renal Tumors. In: Divatia, M., Ozcan, A., Guo, C., Ro, J. (eds) Kidney Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-28333-9_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-28333-9_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-28332-2

  • Online ISBN: 978-3-030-28333-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation